https://ogma.newcastle.edu.au/vital/access/ /manager/Index ${session.getAttribute("locale")} 5 https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:15237 6 months after first- or second-line therapy were randomised to CD or CP for six cycles in this international, open-label, non-inferiority trial. The primary endpoint was progression-free survival. The OS analysis is presented here. Results: A total of 976 patients were randomised (467 to CD and 509 to CP). With a median follow-up of 49 months, no statistically significant difference was observed between arms in OS (hazard ratio=0.99 (95% confidence interval 0.85, 1.16); log-rank P=0.94). Median survival times were 30.7 months (CD) and 33.0 months (CP). No statistically significant difference in OS was observed between arms in predetermined subgroups according to age, body mass index, treatment-free interval, measurable disease, number of lines of prior chemotherapy, or performance status. Post-study cross-over was imbalanced between arms, with a greater proportion of patients randomised to CP receiving post-study PLD (68%) than patients randomised to CD receiving post-study paclitaxel (43%; P<0.001). Conclusion: Carboplatin-PLD led to delayed progression and similar OS compared with carboplatin-paclitaxel in platinum-sensitive ROC.]]> Wed 11 Apr 2018 10:14:17 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:54540 Tue 27 Feb 2024 20:42:11 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:8335 Sat 24 Mar 2018 08:37:01 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:19710 Sat 24 Mar 2018 07:53:42 AEDT ]]>